Marinus Pharmaceuticals (NASDAQ:MRNS) Rating Reiterated by HC Wainwright

Marinus Pharmaceuticals (NASDAQ:MRNS)‘s stock had its “neutral” rating reaffirmed by research analysts at HC Wainwright in a research report issued to clients and investors on Friday, Benzinga reports.

Several other research analysts also recently commented on the company. JMP Securities restated a “market perform” rating on shares of Marinus Pharmaceuticals in a research note on Thursday. StockNews.com upgraded shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, October 4th. Oppenheimer raised shares of Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 target price on the stock in a report on Monday, September 23rd. TD Cowen reissued a “hold” rating on shares of Marinus Pharmaceuticals in a report on Friday. Finally, Royal Bank of Canada reduced their price target on shares of Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating for the company in a research report on Friday. Eight equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $6.07.

Marinus Pharmaceuticals Trading Up 36.9 %

Shares of MRNS stock opened at $0.41 on Friday. The firm’s 50 day moving average is $1.54 and its 200 day moving average is $1.61. The stock has a market capitalization of $22.31 million, a P/E ratio of -0.15 and a beta of 1.14. Marinus Pharmaceuticals has a 12 month low of $0.26 and a 12 month high of $11.26.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01). Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. The business had revenue of $8.06 million for the quarter, compared to the consensus estimate of $9.05 million. During the same period in the previous year, the firm earned ($0.61) EPS. On average, equities analysts predict that Marinus Pharmaceuticals will post -1.93 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC bought a new position in Marinus Pharmaceuticals during the second quarter valued at approximately $727,000. Wellington Management Group LLP boosted its stake in shares of Marinus Pharmaceuticals by 54.8% in the 4th quarter. Wellington Management Group LLP now owns 241,299 shares of the biopharmaceutical company’s stock valued at $2,623,000 after purchasing an additional 85,455 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Marinus Pharmaceuticals by 5.0% during the 1st quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock valued at $25,366,000 after purchasing an additional 132,689 shares during the last quarter. Acadian Asset Management LLC purchased a new position in Marinus Pharmaceuticals in the 2nd quarter worth $813,000. Finally, Hussman Strategic Advisors Inc. lifted its stake in Marinus Pharmaceuticals by 14.3% in the second quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 10,500 shares during the last quarter. Institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.